Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 20, 2021
Reporting Period: Event date December 20, 2021
Inmune Bio, Inc., a Nevada corporation, filed this report to disclose an amendment to its existing Rights Agreement. The Company is an emerging growth company.
Key Financial Metrics
This filing is a current report regarding a corporate governance event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is the execution of Amendment No. 1 to the Rights Agreement originally adopted on December 30, 2020. Key details include:
- Expiration Extension: The expiration date of the Rights Agreement has been extended from December 30, 2021, to December 30, 2022.
- Underlying Instrument: The amendment affects the preferred share purchase rights (Rights) declared as a dividend of one Right for each outstanding share of common stock.
- Counterparty: The agreement remains between Inmune Bio, Inc. and VStock Transfer, LLC as the rights agent.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the Rights are subject to the provisions of the Rights Agreement as amended. The full text of the Amendment is incorporated by reference as Exhibit 4.1.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard governance of the Rights Agreement. The extension of the poison pill mechanism (Rights Agreement) is a defensive measure against potential unsolicited takeover attempts.
Guidance: No financial guidance or operational outlook is provided in this document.
Investor Verification Checklist
- Verify the full text of Amendment No. 1 to the Rights Agreement (Exhibit 4.1) for specific terms regarding the exercise price and trigger events.
- Confirm the current number of outstanding common shares to understand the total number of Rights in circulation.
- Review the original Rights Agreement (filed December 30, 2020) to understand the baseline terms being extended.
- Monitor future filings for any further amendments or the eventual expiration of the Rights on December 30, 2022.